Ustekinumab, delivered subcutaneously, is effective for patients with inflammatory bowel disease (IBD) receiving concomitant treatment for dermatological or rheumatological conditions, a recent study has found.
Namilumab has an acceptable tolerability profile and yields rapid and sustained responses in rheumatoid arthritis (RA) patients with inadequate response to methotrexate or antitumour necrosis factor therapy, according to the results of a phase II trial.
In the treatment of gout, the risk of nonfatal cardiovascular (CV) events, including myocardial infarction and stroke, does not significantly differ between allopurinol and febuxostat, a study has shown.
In patients with early rheumatoid arthritis, those who achieved low disease activity (LDA) after 3 months of methotrexate (MTX) therapy have low baseline levels of C-reactive protein (CRP) and leptin and high baseline levels of tumour necrosis factor receptor I (TNF-RI) and vascular cell adhesion molecule 1 (VCAM-1), according to a recent study. The combination of these four biomarkers increase the accuracy of prediction.
Use of opioids, selective serotonin reuptake inhibitors and glucocorticoids in the treatment of rheumatoid arthritis (RA) is associated with an increased risk of any fracture, whereas statins and tumour necrosis factor inhibitors exert a protective effect on vertebral fracture risk, according to a study.
The CA125* test could be useful at detecting ovarian cancer and various other cancers in the primary care setting, particularly for women aged >50 years, according to a study presented at the recent NCRI** Cancer Conference held in Glasgow, Scotland, UK.